Eli Lilly axes an early-stage PD-L1/TIM-3 bispecific program in latest pipeline cleanup
Three months after Eli Lilly $LLY followed up on its move to highlight a select group of cancer drugs in the pipeline with the elimination of 2 mid-stage oncology programs, the pharma giant is bringing out the ax to lop off an early-stage PD-L1/TIM-3 bispecific.
Its Q2 update today notes that the bispecific is being swept out alongside an anti-inflammatory program for IL-23/CGRP in immunology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.